Media ReleasesCircadian

View All Circadian News


Circadian, Potential new therapy: VGX-100 identified for improving corneal graft survival

- Data published in the scientific journal Investigative Ophthamology & Visual Science generated by investigators at The Schepens Eye Research Institute led by Harvard University Professor Reza Dana.

- VEGF-C markedly up-regulated in corneal graft rejection.

- VGX-100 significantly improved corneal graft survival in a mouse corneal graft model.

- Data indicates potential opportunity for VGX-100 as a therapeutic for major unmet clinical need of improving corneal graft survival.

Melbourne, Australia January 30, 2011– Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY) announced today the publication of data in the scientific journal, Investigative Ophthamology & Visual Science (IOVS), showing that VEGF-C expression is markedly up-regulated in corneal graft rejection. Importantly the data also showed that VEGF-C blockade, through administration of Circadian’s lead development candidate VGX-100, a human antibody against VEGF-C, significantly improved corneal graft survival in an animal model. The data indicates a major new therapeutic opportunity for VGX-100 to improve corneal graft survival.


For further information please download PDF below:

Download this document